Pharmaceutical policy in Italy: Towards a structural change?

Health Policy

Volumn 72, Issue 1, 2005, Pages 53-63

  Ghislandi, Simone ^a   Krulichova, Iva ^a   Garattini, Livio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Generic drugs; Off patent drugs; Pharmaceutical policy; Reference pricing

Indexed keywords

ARTICLE; DRUG COST; DRUG INDUSTRY; HEALTH CARE POLICY; ITALY; PHARMACIST;

EID: 14844316301     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.02.012     Document Type: Article

References (15)

1. Fattore G., Jommi C. The new pharmaceutical policy in Italy. Health Policy. 46(1):1998;21-41
2. Jommi C., Cantù E., Anessi-Pessina E. New funding arrangements in the Italian National Health Service. International Journal of Health and Planning Management. 16:2001;347-368
3. European Observatory on Health Care Systems website (http://www. observatory.dk).
4. Mapelli V., Lucioni C. Spending on pharmaceuticals in Italy: Macro constraints with local autonomy. Value Health. 6:2003;S31-S45
5. Maccani P. Le nuove modalita' di distribuzione dei farmaci: l'esperienza dell'APSS di Trento. Economia e Politica del Farmaco 2004;1:23-7.
6. De Marchi M., Rocchi M. Basic research in the Italian industry. Research and Development Management. 30(1):2002;79-88
7. Garattini L., Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 51(3):2000;149-162
8. Danzon P., Chao L. Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics. 43:2000;311-357
9. Lopez-Casanovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 54:2000;87-123
10. Martina S., Cornago D., Garattini L. Gruppo di studio I.H.A.G.O. Incentivi ai farmaci generici a livello di ASL: l'osservatorio I.H.A.G.O. Farmacoeconomia e percorsi terapeutici. 3(2):2002;71-80
11. Pavcnik N. Do pharmaceutical prices respond to potential out-of-pocket expenses? RAND Journal of Economics. 33(3):2002;469-487
12. Ghislandi S. Generic drugs: regulation and competition in the Italian pharmaceutical industry. MPhil thesis, University of Oxford; 2003.
13. Varian HR. Microeconomic analysis. 3rd ed. New York: WW Norton & Company, 1992.
14. Giuliani G., Selke G., Garattini L. The German experience in reference pricing. Health Policy. 44:1998;73-85
15. Grootendorst P.V., Dolovich L.R., O'Brien B.J., Holbrook A.M., Levy A.R. Impact of reference-based princing of nitrates on the use and costs of anti-anginal drugs. Canadian Medical Association Journal. 165(8):2001;1011-1019